ASH 2022 Conference Coverage
H

ASH 2022 U.S. Myeloma CAR-T Consortium Real World Experience: Factors Associated With Refractoriness or Early Progression After Ide-Cel in Pts With R/R MM

By ASH 2022 Conference Coverage FEATURING Hamza Hashmi
December 22, 2022
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
04:08
CancerGRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
15:54
Paul Richardson

Emerging Strategies in the Management of Relapsed MM

30:59
Houston Methodist Hospital

Overview of Advances in Multiple Myeloma

Feat. S. Ganguly
21:38
Rahul Banerjee

CAR-T Therapy in Myeloma: What's Here and What's Coming So…

34:48
Kenneth Anderson

MM Cured in 2030 - What Are the Next Steps?

Feat. K. Anderson
06:58
Saurabh Chhabra

Summary of the MAMMOTH Trial in R/R Myeloma

06:41
Hamza Hashmi

Idecabtagene Vicleucel vs. Ciltacabtagene Autoleucel: A Sophie'…

21:16
UChicago Medicine

Myeloma 2022: Challenges and Path Forward

Feat. A. Jakubowiak
10:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Feat. T. Martin
45:43
MedNews Week

Multiple Myeloma in 2022: Developments, Directions, and Disparities

Feat. J. Mikhael
13:46
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Bispecific T-Cell Engagers - Early Data and Where Will We…

Feat. R. Orlowski
24:01
ASH 2022 Conference Coverage

ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next B…

Feat. Y. Efebera
34:28
2022 Community Oncology Conference

Treatment Conundrums in Myeloma

Feat. S. Giralt
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
14:41
Zhubin Gahvari

MAMMOTH Trial: Myeloma Outcomes Post Anti-CD38 MoAbs

10:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: Cellular Therapy

Feat. K. Komanduri
12:11
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Pro C…

Feat. T. Martin
Shambavi Richard

Updates in Sequencing Treatment for Early Multiple Myeloma Relapse